Share on LinkedInShare on LinkedIn

ARTICLE · 10 NOVEMBER 2021

Formulation And Administration Claims Asserted In Hatch-Waxman Pass Muster

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Cephalon, Inc. v. Slayback Pharma Ltd. Liab. Co., the Federal Circuit summarily affirmed under Rule 36 the district court's decision that all asserted claims of the asserted patents are not invalid,...

United StatesIntellectual Property

Holding

In Cephalon, Inc. v. Slayback Pharma Ltd. Liab. Co., the Federal Circuit summarily affirmed under Rule 36 the district court's decision that all asserted claims of the asserted patents are not invalid, and that Defendants infringed and induced infringement. Cephalon, Inc. v. Slayback Pharma Ltd. Liab. Co., 456 F. Supp. 3d 594 (D. Del. April 27, 2020), aff'd, 856 Fed. App'x. 309 (Fed. Cir. Aug. 13, 2021), reh'g denied (Fed. Cir. Oct. 15, 2021).1

Background

Teva Pharmaceuticals Int'l GmbH, Cephalon, and Eagle Pharmaceuticals sued Apotex, Fresenius Kabi USA, Mylan Labs., and Slayback Pharma under the Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)(A). Defendants had filed Abbreviated New Drug Applications (“ANDAs”) to market generic versions of Bendeka®. Bendeka®'s active ingredient is bendamustine hydrochloride (referred to by the parties as bendamustine). The patents at issue were U.S. Patent Nos. 9,265,831 (“the '831 patent”), 9,572,797 (“the '797 patent”),

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from